Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
200 participants
INTERVENTIONAL
2005-03-31
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Study hypothesis: Levosimendan diminishes the need for adrenergic inotropic drugs and morbidity and may improve survival after heart valve surgery.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Levosimendan in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy
NCT01188369
Inotropic Treatment With Levosimendan (SimdaxR)in Heart Surgery
NCT01221116
Comparison of the Administration of Levosimendan and Placebo in the Preparation of Critical Patients for Heart Surgery
NCT01595737
Levosimendan in Acute Heart Failure Following Acute Myocardial Infarction.
NCT00324766
Levosimendan for Cardiac Patients Undergoing Major Abdominal Cancer Surgeries
NCT03557255
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Levosimendan
levosimendan
Intravenous infusion, blus 24 mcg/kg in 30-minutes followed by 0.2 mcg/kg/min up to 24 hours
2
placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
levosimendan
Intravenous infusion, blus 24 mcg/kg in 30-minutes followed by 0.2 mcg/kg/min up to 24 hours
placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical signs of cardiac insufficiency
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kuopio University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kuopio University Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pasi K Lahtinen, MD
Role: PRINCIPAL_INVESTIGATOR
Kuopio University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kuopio University Hospital
Kuopio, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
106/2004
Identifier Type: -
Identifier Source: secondary_id
KUH5070178
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.